O rgan transplantation offers a tremendous opportunity for rehabilitation among patients with end-stage organ disease. Although advances in immunosuppressive therapy have dramatically increased the success of clinical organ transplantation, the development of chronic rejection has become the major obstacle to long-term allograft survival and the major cause of late allograft dysfunction and late death in patients (1, 2) . A common morphologic feature of the process is luminal obliteration of hollow structures in organs, which occurs in parallel with its functional deterioration; those changes lead in turn to specific alterations in individual organs, including graft arteriosclerosis in heart grafts, bronchial obliteration in lungs, and vanishing bile ducts in liver transplantation (3) . Chronic allograft rejection now remains as the major cause of kidney functional decline after transplantation and is responsible for up to 7% of all allograft loss every year (4) . In particular, chronic rejection-induced coronary artery disease is the third leading cause of death after cardiac transplantation (5) . Furthermore, this form of rejection is particularly resistant to immunosuppressive drugs (6) .
Nitric oxide (NO) is a potent free radical that is synthesized from amino acid L-arginine by the NO synthases (NOS) and is involved in diverse physiologic and pathophysiologic processes (7) . There are two enzymatic sources of NO in rejecting grafts: endothelial NOS (eNOS), which is constitutively expressed by endothelial cells; and inducible NOS (iNOS), which is increased in smooth muscle cells and inflammatory cells (8, 9) . Inducible NOS is responsible for the production of large bursts of NO (10) . The production of NO was increased excessively during acute rejection, and it has been postulated that NO synthesized by iNOS can enhance rejection processes and that the active iNOS has an important macrophage effect or mechanism in graft rejection (11) . Activated macrophages produce both NO and O 2 Ϫ radicals by means of activation of iNOS (12) , so that iNOS blockers may act as a mediator and attenuate rejection. FR260330 is a newly developed iNOS inhibitor with a novel mechanism of action that inhibits iNOS monomer dimerization and blocks activity of enzyme selectively. Its molecular formula is C 29 H 28 CIF 3 N 6 O 4 S⅐2H 2 O and it has a molecular weight of 653.05. FR260330 inhibited NO production both in rat and human cells in a dose-dependent manner (IC 50 values were approximately 10 nM). When FR260330 was administered orally in rats that were stimulated with endotoxin, it also inhibited NO production in serum dose dependently. Furthermore, FR260330 did not inhibit iNOS activity directly extracted from lipopolysaccharide (LPS)-interferon (IFN)-stimulated RAW264.7 cells (murine macrophage cell line). FR260330 inhibited expression of neither iNOS mRNA nor iNOS protein in LPS-IFN-stimulated RAW264.7 cells. In contrast, FR260330 inhibited dimerization of iNOS protein in LPS-IFN-stimulated RAW264.7 cells. Rat aortic allograft is an attractive experimental model of vascular rejection (13) . The aim of this study was to evaluate the therapeutic effect of FR260330 in prevention of aortic chronic rejection in the rat.
MATERIALS AND METHODS

Animals
Adult (9 -11 weeks old) male ACI (ACI, RT1 a ) donor and Lewis (LEW, RT1 l ) recipient rats were purchased from Harlan Sprague Dawley (Indianapolis, IN) and Charles River (St-Constant, QC), respectively. Donor-recipient strain combinations of ACI-to-LEW rats present high immune responses in the model of rejection and graft-versus-host disease (14) . Each animal was randomly assigned to a dose group; all were housed in controlled light-dark cycles and allowed free access to water and rat chow.
Immunosuppressants
FR260330 and FK506 oral formula and vehicle were supplied by Fujisawa Pharmaceutical Co., Ltd. (Osaka, Japan). Just before oral administration, a double dose of TC5RW was added to polyethylene glycol 400 stock solution by the concentration of FR260330 to the rat. FK506 was obtained as 5-mg capsules, the content of which was suspended in distilled water according to Fujisawa's Prograft Prescribing Information. Oral suspension (0.5 mg/mL) was prepared extemporaneously before administration. FR260330 was administered twice daily and FK506 was administered once daily by gavage at the dose levels and schedules listed below. The volume of each agent administered to each treated rat was adjusted according to each rat's body weight. Isograft group animals did not receive any drug, whereas placebo control animals received vehicle only.
Aortic Segment Transplantation
Donor and recipient rats were anesthetized with intraperitoneal pentobarbital (40 mg/kg). Graft harvest and aortic transplants were performed using a midline abdominal incision. Grafts were harvested from donor animals by excising the abdominal aorta from below the renal arteries to just above the aortic bifurcation, yielding a 1-cm segment. Branches were ligated with 9-0 nylon sutures. Grafts were then flushed and stored in 4°C Ringer's solution. After the recipient's native aorta was removed, grafts were sutured in the orthotopic position with end-to-end anastomoses using 9-0 nylon interrupted sutures (Micruns, Chicago, IL). Animals were allowed access to food and water after surgery.
Tissue Processing and Morphometric Analysis
Recipient rats were killed on day 14 or day 90 after aortic transplantation. Each graft was harvested at least 2 mm from the suture line, and sections were taken only from the midgraft region so that histologic analysis was carried far away from the suture line. During harvesting, half of the fresh aortic samples were snap-frozen immediately in isopentane precooled by liquid nitrogen for immunopathologic assay. The other half of the samples were fixed in 10% buffered formalin immediately for histology. Paraffin cross-sections were cut into 7-m-thick sections, and 10 consecutive sections were taken at least 300 m apart to obtain as representative a sample as possible from each animal. At least three separate sections were chosen from different parts of the aortic graft. Slides were stained routinely with hematoxylin-eosin. Digital images were collected directly using a Nikon microscope with a 10ϫ objective lens. Intimal and medial layer thicknesses were measured from the square measurements of each different vessel section per aorta graft, using an imaging system, MetaMoph Version Meta Series 6.0 (Universal Imaging Corporation, Downingtown, PA). The internal elastic lamina of each cross-section was carefully traced and the area inside the internal elastic lamina was determined. The intimal area was then calculated by subtracting the nonoccluded luminal area from the area inside the internal elastic lamina. Likewise, the medial area of each graft was calculated by measuring the area inside the external elastic lamina or outer perimeter of the media and then subtracting the area within the internal elastic lamina. Three readings were made on each graft to obtain an average area. To account for the variations in graft circumference, percentage intima values were calculated by dividing the intimal area by the area within the external medial perimeter (intima/intimaϩmedia). Mean areas and standard deviations were calculated for each group.
Analysis ␣-Actin-Positive Cells
A monoclonal antibody (HHF35) that recognizes the ␣ isotype of skeletal, cardiac, and vascular smooth muscle cells was used to detect ␣-actin in all aortic samples. This monoclonal antibody (BioGenex, San Ramon, CA) belongs to the immunoglobin G 1 class and was obtained from mouse ascitic fluid. It was diluted in phosphate-buffered saline, pH 7.6, with 1% bovine serum albumin. The great advantage of this antibody is that it recognized its epitope in paraffin-embedded tissue sections. It is nonreactive with other mesenchymal cells and all epithelial cells except myoepithelium. The recommended positive control is smooth muscle, and in this experiment, normal aortic smooth muscle served as a reliable positive control.
The antibody was added to the specimen and allowed to incubate for 30 min and then rinsed for an additional 30 min. The biotinylated antimouse secondary antibody, anti-immunoglobulin horseradish peroxidase (BD Biosciences, Minneapolis, MN), was added and allowed to incubate for 1 hr followed by rinsing with phosphate-buffered saline. The substrate used was 3,3-diaminobenzidine hydrochloride, which was incubated with the specimen for 15 min. After brief rinsing, paraffin sections were counterstained with hematoxylin alone (15) .
Design of Experiments
Fourteen groups of randomly assigned LEW recipient rats (nՆ6 per group) were used in this study (Figs. 1 and 2 and Tables 1 and 2 ). Recipient rats were treated daily with FR260330, FK506, or both in different doses by gavage immediately after surgery for 14 or 90 days. Group 1 isograft control recipients (LEW-to-LEW) did not receive any drugs. Group 2 placebo allograft controls (ACI-to-LEW) received vehicle of FR260330 only. Groups 3 and 4 allograft recipients were administered FR260330 (10 and 32 mg/kg twice daily); whereas in groups 5 and 6, allograft recipient rats were treated with FK506 (1.0 and 2.0 mg/kg per day once daily, respectively). A combination therapy of FR260330 10 (mg/kg twice daily) with FK506 (1.0 mg/kg per day once daily) was performed in group 7. Recipient body weight was measured weekly throughout the study (Fig. 3) .
Statistical Analysis
Results of all rat body weight changes and intima and intima/(intimaϩmedium) ratios of aortic grafts are presented as meanϮSD. Ratios for the experimental and control groups were analyzed using one-way analysis of variance. Tukey's test was used to provide P values for all pairwise multiple comparison procedures or Dunnett's test to provide P values in multiple comparisons versus control group. PϽ0.05 was considered to be statistically significant.
RESULTS
Intimal Hyperplasia and Intima Ratios
Rat aortic allografting is an attractive experimental model of vascular rejection. This model allows a specific focus on the arterial wall for immunologic targeting and response induced by allografting, because of the plain structural organization of arterial wall in three easily identifiable differentiated cell layers: the endothelium (intima), the media, and the adventitia. Chronic experimental arterial allograft rejection has already been characterized into three major components: adventitial inflammatory infiltration, medial degeneration or necrosis, and intimal proliferation (11) .
Intimal and medial area and intima/(intima؉media) ratio
The intima of isografts presented as normal with a monolayer of aortic endothelial cells forming a smooth inner lining. The smooth muscle cells were absent from anti-␣-actin staining in all intimas in isograft controls Fig. 5 (2) up to 90 days after transplantation. There were dense smooth muscle cells arranged in an orderly fashion along with several separate concentric plastic fibers in the media. Smooth muscle cells were positively stained after exposure to anti-␣-actin monoclonal antibody Fig. 5 (2) . Untreated allografts displayed progressive hyperplasia with a characteristic feature of graft arteriosclerosis with extensive hyperplasia of neointima and the loss of cellularity in the medial layer with a concomitant decrease in size. The surface of the endothelium was damaged partially, and there was much mononuclear cell infiltration surrounding the adventitia in the placebo control group (group 2) Figs. 4 (2) and 5 (1).
Compared with the untreated allograft controls (group 2), the intima area ( Fig. 1 and Table 1 ) and the percentage of intima (ratios of intima/intimaϩmedia) ( Fig. 2 and Table 2) were markedly reduced in the FR260330-and FK506-treated groups up to 90 days, with ratios of 1.2% in the isograft control group (group 1), 86.6% in the placebo control group (group 2), 43.1% in the FR260330 20 mg/kg per day-treated group (group 3), 34.9% in the FR260330 64 mg/kg per daytreated group (group 4), 39.2% in the FK506 1.0 mg/kg per day-treated group (group 5), 2.5% in the FK506 2.0-treated group (group 6), and 17.96% in the FR260330 20 mg/kg per day combined with FK506 1.0 mg/kg group (group 7), respectively. Both low and high doses of FR260330 were effective in preventing intimal hyperplasia compared with naive controls up to 90 days after surgery. Combination therapy of low-dose FR260330 20 mg/kg per day with FK506 1.0 mg/kg per day in group 7 significantly reduced the percentage of intima hyperplasia and the ratios compared with single drug use only (group 7 vs. group 3, PϽ0.05 for intima and PϽ0.05 for ratio; group 7 vs. group 5, PϾ0.05 for intima and PϽ0.05 for ratio). The analyses of ratios of intima/(intimaϩmedia) in Figure 2 and Table 2 are more accurate and reasonable than only intimal area assessment in Figure 1 and Table 1 . First, during processing of pathologic findings, it was difficult to guarantee each cross-section being a coronary plane. If an oblique plane occurred, the intimal area would be deviated. Second, if rats' weights were different, the diameter of the aorta would be different also and, consequently, the intimal area would be different. Third, even in the same aortic graft, the cross-sections were cut from different parts of the aorta, and the diameters would also be different. The ratio of intima/ (intimaϩmedia) in Figure 2 and Table 2 can avoid these technical deviations. This is why the difference between group 7 and group 4 and group 5 in Figure 1 and Table 1 was not significant but becomes significant in Figure 2 and Table  2 . There were no significant differences of intima and intima ratios in the seven groups observed for 14 days after transplantation (data not shown).
␣-Actin-Positive Cell Staining
Smooth muscle cells are positively stained after exposure to anti-␣-actin monoclonal antibody. ␣-Actin staining was performed 14 days and 90 days after aortic transplantation in all samples in each group. Intimal hyperplasia was minimal at 14 days, without a significant difference. There was strong ␣-actin staining in the cells in the neointima in control group 2 and in other groups (data not shown). When the process of migration of smooth muscle cells and other cells into intima was mature at 90 days, ␣-actin-positive staining cells were randomly distributed throughout the neointima Fig. 5 (1) and (3) and were located mainly on the luminal side of the neointima (Fig. 54) . In syngeneic controls, all ␣-actin-positive staining cells were located in the media Fig. 5 (2) ; smooth muscle cells in the media in allograft controls were absent Fig. 5 (1) .
Body Weight Changes
Body weight decreased in most recipient rats in the first 3 days after aortic transplantation because of surgical trauma. A high dose of FK506 (2.0 mg/kg/day) in recipients in group 3. Body weight gain. Body weight in each rat was measured before dosing every day up to 90 days after surgery. Body weight gains are presented in each group. High-dose FK506 (2.0 mg/kg/day) treatment in group 6 led to body weight loss in the first 2 weeks but recovered to group 2, placebo control without significant difference on the termination of day 90 after surgery (Pϭ0.08). With the treatment of FR260330 in groups 3, 4, and 7, the rat weight gained gradually, the same as placebo control up to day 90 after surgery (PϾ0.05).
6 led to body weight loss in the first 2 weeks but slowly recovered to group 2, placebo control, without significant differences on the termination of day 90 after surgery (Pϭ0.08) (Fig. 3) . In group 1, isograft control, rat weight increased gradually until week 8 and then remained stable up to day 90. With the treatment of a low dose of FR260330 (20 mg/kg/day) in group 3 and a high dose of FR260330 (64 mg/kg/day) in group 4, or combined therapy of FR260330 (20 mg/kg/day) with FK506 (1.0 mg/kg) in group 7 up to day 90, the weight of the rats increased gradually, the same as placebo controls (PϾ0.05). We have not found any specific toxicity in rats treated with FR260330 in this study.
DISCUSSION
In the present study, the authors have tested monotherapy and combination therapy of FR260330, a novel iNOS inhibitor, with FK506 in prevention of chronic aortic rejection in the rat. Both low-and high-dose FR260330 therapies significantly inhibit intimal hyperplasia compared with naive controls (PϽ0.05) up to 90 days. Combination therapy of low-dose FR260330 (20 mg/kg/day) and low-dose FK506 (1.0 mg/kg/day) significantly reduced the percentage of intima hyperplasia compared with single drug use only (PϽ0.05).
NO has been indicated as a potential mediator in the development of transplant arteriosclerosis. There are two enzymatic sources of NO in rejecting grafts: eNOS, which is constitutively expressed by endothelial cells; and iNOS, which is increased in smooth muscle cells (SMC) and inflammatory cells (8, 9) . NO synthesized by iNOS may enhance rejection processes and the active iNOS has an important macrophage effect or mechanism in graft rejection (11, 16) . Inducible NOS can be expressed in vascular SMC and macrophages and is calcium-independent and typically expressed in cells after exposure to inflammatory mediators. FR260330 is a potent iNOS inhibitor that can effectively prevent intima hyperplasia by means of inhibiting SMC, macrophages, and any inflammatory cell migration to the intima.
In the FK506-treated aortic grafts, we observed a marked reduction of intima hyperplasia, especially in the high-dose FK506 group. Cyclosporine A (CsA) also effectively inhibited intimal hyperplasia in the same model (17) . CsA regulates cell proliferation in an interleukin-2-independent fashion by augmenting the production of transforming growth factor-␤, an inhibitor of SMC proliferation and a potent stimulator of extracellular matrix deposition (18) . The role of transforming growth factor-␤ in chronic rejection may be concentration dependent in that inhibition of SMC proliferation occurs at nanomolar concentrations, whereas the stimulation of extracellular matrix deposition occurs at femtomolar concentrations. FK506 inhibits T-lymphocyte immune response by the same means as CsA to blockade the calcium-dependent signaling pathway, thus inhibiting interleukin-2 gene transcription. FK506 is a potent immunosuppressant that is 10-to 100-fold stronger than CsA in both experimental and clinical transplantation (19, 20) . Thus, combination therapy of low-dose FR260330 and FK506 in which the mechanisms of action in prevention of chronic rejection are different will produce synergistic or additive effects to prevent chronic rejection. The authors' present results show that FK506 2.0 mg/kg per day treatment in group 6 is strong enough to inhibit the intimal proliferation, which is similar to isograft control in group 1 (PϾ0.05) (Figs. 1 and 2 and Tables 1 and 2 ). In this circumstance, it was not necessary to combine FK506 2.0 mg/kg per day with FR260330 for drug interaction. Furthermore, long-term treatment of FK506 2.0 mg/kg per day is a marginal dose with which to induce nephrotoxicity in the rat according to our previous study in chronic renal rejection (Tilney model, data not shown). Therefore, combination therapy with a low-dose of FR260330 and a low-dose of FK506 in prevention of chronic transplant arteriosclerosis is suggested.
The phenomenon the authors observed in this study is similar to other observations (13, 15, 17, (21) (22) (23) (24) in that the intimal proliferation was associated with a concomitant loss of the medial SMC at the same time after transplantation. ␣-Actin-positive cells were the predominant proliferating cells, and macrophages and lymphocytes infiltrated diffusely throughout the intimal thickening. Johnson et al. (23) proved that neointimal cells of recipient origin provide definite direct NO has multiple well-described actions in the circulation. Several controversial results were described by Sears et al. and Lee et al. (25, 26) showing that iNOS inhibitor increased the intimal thickening in a rat aortic allograft model and that adenovirus-mediated iNOS gene transfer completely suppressed the development of allograft arteriosclerosis. Lee et al. demonstrated that aortic allograft arteriosclerosis in eNOS knockout mice and ex vivo iNOS gene transfer completely prevented the development of arteriosclerosis associated with eNOS deficiency. Sometimes, treatment of inhibition of iNOS or iNOS gene deletion does not completely abolish the protection, indicating that iNOS is important for ischemia-reperfusion injury but does not account for the entire phenomenon. NO may have a protective effect because of its antiapoptosis action and effects to decrease leukocyte-endothelium interactions. NO can result in vasodilatation and inhibition of platelet plug formation and reduction of the inflammatory response. In contrast, NO can induce injury by means of lipid peroxidation, DNA damage, and proapoptotic effects, which are implicated in ischemic injury. Goligorsky et al. (27) demonstrated that the cellular effects of NO depend on its concentration, site of release, and duration of action. Low levels of NO may be protective but higher levels may be detrimental. Nathan (28) reviewed iNOS: what difference does it make? It is already clear that expression of iNOS sometimes makes a profound difference in the course of infection or inflammation in mice. There is no basic experiment with which to reject the presumption that iNOS may play a similar role in humans. Inducible NOS appears to act as a direct effector and as a regulator of other effectors. The impact of iNOS is potentially dichotomous, and the dichotomy is sometimes manifested at different times or sites in the same experimental setting. These complexities do not preclude experimental therapeutic intervention but demand caution to trial with an iNOS inhibitor.
CONCLUSION
A selective inhibitor of NOS, FR260330 significantly reduces intimal hyperplasia in rat aortic transplants. Combination therapy of low-dose FR260330 with tacrolimus produces significant protection of immune injury and may serve to improve long-term graft survival and function. 
